Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

AIDS

Volumn 13, Issue 4, 1999, Pages 473-478

  Dieleman, Jeanne P ^a   Gyssens, Inge C ^a   Van Der Ende, Marchina E ^a   De Marie, Siem ^a   Burger, David M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV infection; HIV protease inhibitors; Indinavir; Kidney; Plasma concentration; Risk factors; Therapy; Urinary calculi

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; URINARY TRACT DISEASE; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; UROLOGIC DISEASES; VIRAL LOAD;

EID: 0033545478     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199903110-00005     Document Type: Article

References (15)

1. Crixivan® (indinavir sulfate) product monograph. Whitehouse Station, NJ, USA: Merck and Co., 1996.
2. Kopp JB, Miller KD, Mican JA, et al.: Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997, 127:119-125.
3. Berns JS, Cohen RM, Silverman M, Turner J: Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997, 30:558-560.
4. Sutherland SE, Reigle MD, Seftel AD, Resnick MI: Protease inhibitors and urolithiasis. J Urol 1997, 158:31-33.
5. Bruce RG, Munch LC, Hoven AD, et al.: Urolithiasis associated with the protease inhibitor indinavir. Urology 1997, 50:513-518.
6. Gentle DL, Stoller ML, Jarrett TM, Ward JF, Geib KS, Wood AF: Protease inhibitor-induced urolithiasis. Urology 1997, 50:508-511.
7. Balani SK, Woolf EJ, Hoagland VL, et al.: Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996, 24:1389-1394.
8. Daudon M, Estepa L, Viard JP, Joly D, Jungers P: Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997, 349:1294-1295.
9. Burger DM, De Graaff M, Wuis FW, Koopmans PP, Hekster Y: Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 1997, 703:235-241.
10. Stein DS, Fish DG, Bilello, Preston SL, Martineau GL, Drusano GI : A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996, 10:485-492.
11. Burger DM, Koopmans PP, Brinkman K, et al.: Therapeutic drug monitoring of the HIV protease inhibitor indinavir. 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract A-19].
12. Lin JH, Chen IW, Vastag KI, Ostovic D: pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 1995, 23:730-735.
13. Bach MC, Godofsky TW: Indinavir nephrolithiasis in warm climates. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:296-298.
14. Chiba M, Hensleigh M, Lin JH: Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 1997, 53:1187-1195.
15. Burger DM, Koopmans PP, Brinkman K: Influence of gender on indinavir pharmacokinetics. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, October 1997 [abstract 252].